chimeric fusion protein (Attralus/University of Limoges)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namechimeric fusion protein (Attralus/University of Limoges)
Drug Alias Namechimeric fusion protein (Attralus)AT-03 (Attralus)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitorsMacrophages stimulants
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAmyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversite De Limoges
China Registration ClassN/A

Develop Information

Active CompaniesUniversite De LimogesAttralus Inc
Inactive CompaniesN/A
Active IndicationsAmyloidosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A